Tralokinumab-ldrm Shows Significant Improvements in Symptoms of Atopic Dermatitis

Tralokinumab-ldrm is an interleukin-13 antagonist recently approved for the treatment of moderate-to-severe atopic dermatitis.

Treatment with tralokinumab-ldrm (Adbry; LEO Pharma) produced significant improvements in itch, sleep interference, anxiety, depression, and overall quality of life among patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD). The new 16-week data were presented at the Western Society of Allergy, Asthma and Immunology (WSAAI) 59th annual scientific session held February 6-10, in Maui, Hawaii.

Tralokinumab-ldrm is an interleukin-13 (IL-13) antagonist recently approved for the treatment of moderate-to-severe AD in patients 18 years of age or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Tralokinumab-ldrm is the first FDA-approved biologic that specifically binds to and inhibits the IL-13 cytokine, according to LEO Pharma. The new data showed patient-reported outcomes with tralokinumab-ldrm at 150 mg or 300 mg every 2 weeks, compared to placebo at week 16 in the 52-week monotherapy phase 3 ECZTRA 6 trial (NCT0356861).

Other results from the trial included:1

  • After 16 weeks, significantly more adolescent patients achieved improvements with tralokinumab-ldrm 150 mg (n=100) or 300 mg (n=101) every 2 weeks compared to placebo (n=100).
  • Use of a 4-point or greater improvement in adolescent Worst Daily Pruritus Numeric Rating Scale showed that placebo patients did not improve as much as their treated counterparts (23.2% tralokinumab-ldrm 150 mg [P<.001], 25.0% tralokinumab-ldrm 300 mg [P<.001], 3.3% placebo).
  • A 6-point or greater improvement in Children’s Dermatology Life Quality Index (31.0% tralokinumab-ldrm 150 mg [P=.029], 39.5% tralokinumab-ldrm 300 mg [P<.001], 15.9% placebo).
  • A 6-point or greater improvement in Patient Oriented Eczema Measure (38.7% tralokinumab-ldrm 150 mg [P<.001], 46.8% tralokinumab-ldrm 300 mg [P< .0001], 10.5% placebo).
  • At week 16, tralokinumab-ldrm was associated with greater improvement vs placebo in eczema-related sleep NRS (weekly average).
  • At week 16, tralokinumab-ldrm 300 mg was also associated with greater improvement compared to placebo in Hospital Anxiety and Depression Scale.

Reference:

1. Soong et al. Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks. WSAAI. Feb 6-10, 2022. Maui, HI. Poster Presentation.